PF-Atlas › Clinical Trials › NCT00408317

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Ultrase® MT20 · Phase 3

Registry ID

NCT00408317

Phase

Phase 3

Status

Completed

Drug / intervention

Ultrase® MT20

Sponsor

Forest Laboratories

Start

2006-11

About this trial

Ultrase® MT20 is evaluated in NCT00408317, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Forest Laboratories. Current status: Completed.

View NCT00408317 on ClinicalTrials.gov →

Explore related

All Ultrase® MT20 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00408317 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.